S 234462Alternative Names: S-234462
Latest Information Update: 12 Nov 2016
At a glance
- Originator Shionogi
- Class Obesity therapies
- Mechanism of Action Neuropeptide Y5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 11 Aug 2011 Phase I development is ongoing in USA
- 17 Feb 2010 Phase-I clinical trials in Obesity in USA (PO)